fink. i have a question about the fda's review of efficacy data. your slide indicated a november 30th submission for the eua. the documents indicate that moderna submitted another set of documents on 12/7 and that included the data of 11/21. in the briefing document you indicated fda had reviewed some and verified some of that recent data but not all. just briefly explain what that actually means, and there's been reports in the press about how the fda's process is more rigorous than the british review process, for example. but explain what that really means. and second, to confirm that you have been able to verify the efficacy data in the second set prior to primary employ as well as the important secondary end point of any severe disease. >> yes, we'll hear more about that in our fda presentation this afternoon but i can verify, i can confirm that fda has examined, verified the integrity of and confirmed the efficacy analyses from the later on point, from the november 21st time point, both for the primary efficacy analysis and for the secondary a

let's start out with mr. tub. >> i read this before. data is now 26 days old. that was the closing date. i asked the question about do we have more recent data? dr. fink does not have any. however, the sponsor here. they will have updated data. some other folks they were asking about it. i have one specific set of data i would like to ask about it. it is about this question of severe disease. pfizer suggests it has been demonstrated the vaccine is effective with severe disease but that is not really the case. in your briefing document, you just don't have enough data to know that. is, do we have such data? is an efficacy of 56%, not the other data you talked about from dose one. the actual endpoint and the study came up with 56% efficacy. that is the thing that really matters and we care about. almost nobody cares about covid-19 at all if you have a sore throat. it is in the public interest to know what is the public interest in the vaccine. you do not have sufficient data to conclude that as of november 14. can we get data? pfizer which from shows additional c

black rock was involved in the financial crisis last time, larry fink has enormous experience, so that is one of them that has been disclosed and as we hire hora people we will fully disclose it. >> brennan: mr. secretary, i appreciate all of what you are doing in that you are saying it is going to take time to see if it is going to be successful or not, but do you need to level with the american people here and tell them, you simply don't know that all of these jobs are going to come back? i mean, the president of the st. louis federal reserve bank said we could see unemployment hit 30 percent in the second quarter of this year. you saw 3 million people file for unemployment this week. >> well, let me clarify. i never said we didn't know if this will be successful or not. i think this is program is going to be enormously successful in stabilizing the u.s. economy while hardworking americans who lost their jobs or aren't able to work because of the medical situation that they get help. so this money is going to go into the economy very quickly. it is going to help american workers very

i am proud to present the mr. paul loan. >> fink you for your persistence continuing to focus on crushing what you just said, you constantly said, it has to be the focus because it is the key to everything. you will not be able to recover the economy unless you crush the virus. this is emphasis that the government's responsibility, washington's responsibility, to do something about this. i have not been part of the negotiations but whenever she talks to us, i know when the president raises one issue, she says what about the virus in the testing, what will you do about for, so i want to thank you prioritizing and constantly saying it up. it is hard for me to believe it is now october, 10 months into the pandemic, and the trump administration does not have a national testing tracing surveillance and containment plan in place. we have asked for this since the beginning. we cannot even contain covid within the confines of the white house. i heard he is back in the oval office, potentially spreading this to the people

. >> now, mr. secretary, i guess my question would be acknowledging what you've just stated and it's very similar to many of the administration, being realistic, mr. fink expressed similar viewpoints is there anything that could be done to ease the transition above and beyond ppp and some of the current programs >> well, you know, i think that technology is playing a lot bigger role, especially in the covid-19 era, and i think it's going to continue. so we need to be thinking a bit long-term and how do we retrain some of the folks. obviously attracting foreign investment is key. i know the administration is doing a lot to bring back manufacturing, especially from china, from other countries. that can add, but there's nothing like preparing workers for what's coming, and i do think that we have made a leap in terms of technology we've gone to a new level during this co-vid era, because these technology tools have helped us. and -- but they will also take some jobs. and preparing people for that new